PRKCD and breast cancer: In recent works, again through PKCδ inhibition, 2.5–10 μM Rottlerin treatment decreased MMP-12 levels and invasiveness of tenascin-stimulated glioma cells [92] and caused a marked decrease in PMA-induced MMP-9 secretion and invasiveness in MCF-7 human breast cancer cells [93].